Literature DB >> 25756799

Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential.

Erika M Yazawa1, Jenna E Geddes-Sweeney1, Filiberto Cedeno-Laurent1, Kempland C Walley1, Steven R Barthel2, Matthew J Opperman1, Jennifer Liang1, Jennifer Y Lin2, Tobias Schatton2, Alvaro C Laga3, Martin C Mihm2, Abrar A Qureshi4, Hans R Widlund1, George F Murphy3, Charles J Dimitroff5.   

Abstract

Galectin-1 (Gal-1)-binding to Gal-1 ligands on immune and endothelial cells can influence melanoma development through dampening antitumor immune responses and promoting angiogenesis. However, whether Gal-1 ligands are functionally expressed on melanoma cells to help control intrinsic malignant features remains poorly understood. Here, we analyzed expression, identity, and function of Gal-1 ligands in melanoma progression. Immunofluorescent analysis of benign and malignant human melanocytic neoplasms revealed that Gal-1 ligands were abundant in severely dysplastic nevi, as well as in primary and metastatic melanomas. Biochemical assessments indicated that melanoma cell adhesion molecule (MCAM) was a major Gal-1 ligand on melanoma cells that was largely dependent on its N-glycans. Other melanoma cell Gal-1 ligand activity conferred by O-glycans was negatively regulated by α2,6 sialyltransferase ST6GalNAc2. In Gal-1-deficient mice, MCAM-silenced (MCAM(KD)) or ST6GalNAc2-overexpressing (ST6(O/E)) melanoma cells exhibited slower growth rates, underscoring a key role for melanoma cell Gal-1 ligands and host Gal-1 in melanoma growth. Further analysis of MCAM(KD) or ST6(O/E) melanoma cells in cell migration assays indicated that Gal-1 ligand-dependent melanoma cell migration was severely inhibited. These findings provide a refined perspective on Gal-1/melanoma cell Gal-1 ligand interactions as contributors to melanoma malignancy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25756799      PMCID: PMC4466041          DOI: 10.1038/jid.2015.95

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  67 in total

1.  High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion.

Authors:  Ha-Jeong Kim; Hye-Kyung Jeon; Young Jae Cho; Young Ae Park; Jung-Joo Choi; In-Gu Do; Sang Young Song; Yoo-Young Lee; Chel Hun Choi; Tae-Joong Kim; Duk-Soo Bae; Jeong-Won Lee; Byoung-Gie Kim
Journal:  Eur J Cancer       Date:  2012-03-02       Impact factor: 9.162

2.  Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma.

Authors:  Filiberto Cedeno-Laurent; Rei Watanabe; Jessica E Teague; Thomas S Kupper; Rachael A Clark; Charles J Dimitroff
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

3.  Galectin-1 in melanoma biology and related neo-angiogenesis processes.

Authors:  Véronique Mathieu; Elisabeth Martin de Lassalle; Jaan Toelen; Thomas Mohr; Akeila Bellahcène; Gwendoline Van Goietsenoven; Tina Verschuere; Caroline Bouzin; Zeger Debyser; Steven De Vleeschouwer; Stefaan Van Gool; Françoise Poirier; Vincent Castronovo; Robert Kiss; Olivier Feron
Journal:  J Invest Dermatol       Date:  2012-05-24       Impact factor: 8.551

4.  Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.

Authors:  Diego O Croci; Juan P Cerliani; Tomas Dalotto-Moreno; Santiago P Méndez-Huergo; Ivan D Mascanfroni; Sebastián Dergan-Dylon; Marta A Toscano; Julio J Caramelo; Juan J García-Vallejo; Jing Ouyang; Enrique A Mesri; Melissa R Junttila; Carlos Bais; Margaret A Shipp; Mariana Salatino; Gabriel A Rabinovich
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

5.  Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer.

Authors:  S Iacobelli; E Arnò; A D'Orazio; G Coletti
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

6.  Endogenous ligands of rat lung beta-galactoside-binding protein (galaptin) isolated by affinity chromatography on carboxyamidomethylated-galaptin-Sepharose.

Authors:  J T Powell; P L Whitney
Journal:  Biochem J       Date:  1984-11-01       Impact factor: 3.857

7.  Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen.

Authors:  Nuno T Marcos; Sandra Pinho; Catarina Grandela; Andrea Cruz; Bénédicte Samyn-Petit; Anne Harduin-Lepers; Raquel Almeida; Filipe Silva; Vanessa Morais; Julia Costa; Jan Kihlberg; Henrik Clausen; Celso A Reis
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

Review 8.  CD146, a multi-functional molecule beyond adhesion.

Authors:  Zhaoqing Wang; Xiyun Yan
Journal:  Cancer Lett       Date:  2012-12-21       Impact factor: 8.679

9.  An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor.

Authors:  Nirupa Murugaesu; Marjan Iravani; Antoinette van Weverwijk; Aleksandar Ivetic; Damian A Johnson; Aristotelis Antonopoulos; Antony Fearns; Mariam Jamal-Hanjani; David Sims; Kerry Fenwick; Costas Mitsopoulos; Qiong Gao; Nick Orr; Marketa Zvelebil; Stuart M Haslam; Anne Dell; Helen Yarwood; Christopher J Lord; Alan Ashworth; Clare M Isacke
Journal:  Cancer Discov       Date:  2014-02-11       Impact factor: 39.397

10.  Identification of galectin-1 as a critical factor in function of mouse mesenchymal stromal cell-mediated tumor promotion.

Authors:  Gábor János Szebeni; Éva Kriston-Pál; Péter Blazsó; Róbert László Katona; Julianna Novák; Enikő Szabó; Ágnes Czibula; Roberta Fajka-Boja; Beáta Hegyi; Ferenc Uher; László Krenács; Gabriella Joó; Éva Monostori
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

View more
  14 in total

1.  MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding.

Authors:  I Made Winarsa Ruma; Endy Widya Putranto; Eisaku Kondo; Hitoshi Murata; Masami Watanabe; Peng Huang; Rie Kinoshita; Junichiro Futami; Yusuke Inoue; Akira Yamauchi; I Wayan Sumardika; Chen Youyi; Ken-Ichi Yamamoto; Yasutomo Nasu; Masahiro Nishibori; Toshihiko Hibino; Masakiyo Sakaguchi
Journal:  Clin Exp Metastasis       Date:  2016-05-05       Impact factor: 5.150

2.  I-branched carbohydrates as emerging effectors of malignant progression.

Authors:  Charles J Dimitroff
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-18       Impact factor: 11.205

3.  MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.

Authors:  Satyendra C Tripathi; Johannes F Fahrmann; Muge Celiktas; Mitzi Aguilar; Kieren D Marini; Mohit K Jolly; Hiroyuki Katayama; Hong Wang; Eunice N Murage; Jennifer B Dennison; D Neil Watkins; Herbert Levine; Edwin J Ostrin; Ayumu Taguchi; Samir M Hanash
Journal:  Cancer Res       Date:  2017-06-23       Impact factor: 12.701

Review 4.  Galectin-Binding O-Glycosylations as Regulators of Malignancy.

Authors:  Charles J Dimitroff
Journal:  Cancer Res       Date:  2015-07-29       Impact factor: 12.701

5.  Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8+ regulatory T cells.

Authors:  Alejandro J Cagnoni; María Laura Giribaldi; Ada G Blidner; Anabela M Cutine; Sabrina G Gatto; Rosa M Morales; Mariana Salatino; Martín C Abba; Diego O Croci; Karina V Mariño; Gabriel A Rabinovich
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-25       Impact factor: 11.205

6.  Activated fibroblasts enhance cancer cell migration by microvesicles-mediated transfer of Galectin-1.

Authors:  Alessandra Toti; Alice Santi; Elisa Pardella; Ilaria Nesi; Richard Tomasini; Tommaso Mello; Paolo Paoli; Anna Caselli; Paolo Cirri
Journal:  J Cell Commun Signal       Date:  2021-05-22       Impact factor: 5.782

7.  Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma.

Authors:  Federica Felicetti; Alessandra De Feo; Carolina Coscia; Rossella Puglisi; Francesca Pedini; Luca Pasquini; Maria Bellenghi; Maria Cristina Errico; Elena Pagani; Alessandra Carè
Journal:  J Transl Med       Date:  2016-02-24       Impact factor: 5.531

Review 8.  T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.

Authors:  Robert Sackstein; Tobias Schatton; Steven R Barthel
Journal:  Lab Invest       Date:  2017-03-27       Impact factor: 5.662

Review 9.  Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities.

Authors:  Emily Rodrigues; Matthew S Macauley
Journal:  Cancers (Basel)       Date:  2018-06-18       Impact factor: 6.639

Review 10.  Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.

Authors:  Patrick A Ott; F Stephen Hodi; Elizabeth I Buchbinder
Journal:  Front Oncol       Date:  2015-09-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.